NCT04405739View on ClinicalTrials.gov

The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID)

PHASE2CompletedINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

June 16, 2020

Primary Completion Date

February 21, 2022

Study Completion Date

February 21, 2022

Conditions
SARS-CoV 2
Interventions
DRUG

EIDD-2801

Oral capsule of EIDD-2801

DRUG

Placebo

Oral placebo capsule

Trial Locations (11)

21044

Howard County General Hospital, Columbia

21224

Johns Hopkins Bayview Medical Center, Baltimore

21287

John Hopkins Hospital, Baltimore

27157

Wake Forest Baptist Health, Winston-Salem

37235

Vanderbilt University, Nashville

60068

Advocate Lutheran General Hospital, Park Ridge

60453

Advocate Christ Medical Center, Oak Lawn

60612

Cook County Hospital, Chicago

71101

Ochsner LSU Health Shreveport Academic Medical Center, Shreveport

77030

Houston Methodist Hospital, Houston

90095-8358

Ronald Reagan UCLA Medical Center, Los Angeles

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Ridgeback Biotherapeutics, LP

INDUSTRY

NCT04405739 - The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID) | Biotech Hunter | Biotech Hunter